Form 4: Karyopharm Therapeutics EVP Stuart Poulton Sells Shares to Cover Tax Obligations
SEC Form 4
Stuart Poulton, EVP and Chief Development Officer of Karyopharm Therapeutics, sold 5,914 shares of common stock to cover withholding tax liability.
Summary
- On February 18, 2025, Stuart Poulton, EVP and Chief Development Officer of Karyopharm Therapeutics Inc., sold 5,914 shares of common stock.
- The sale was executed at a price of $0.63 per share.
- The transaction was conducted under a pre-arranged automatic sale plan adopted on May 18, 2022, to cover withholding tax obligations arising from the vesting of restricted stock units.
- Following the transaction, Poulton directly owns 320,714 shares of Karyopharm Therapeutics Inc.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine sale of shares to cover tax obligations and doesn't necessarily reflect a positive or negative outlook on the company.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects.
Key Dates
| Date | Description |
|---|---|
| May 18, 2022 | Date the reporting person adopted the durable automatic sale instruction plan. |
| February 18, 2025 | Date of the transaction (stock sale). |
| February 19, 2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.